PortalPublikationenDeletion of 3p13 is a late event linked to progression of TM...

Deletion of 3p13 is a late event linked to progression of TMPRSS2:ERG fusion prostate cancer

Standard

Deletion of 3p13 is a late event linked to progression of TMPRSS2:ERG fusion prostate cancer. / Kluth, Martina; Volta, Heinke; Hussein, Mohammad; Taskin, Billurvan; Frogh, Sohall; Möller-Koop, Christina; Büscheck, Franziska; Jacobsen, Frank; Tsourlakis, Maria Christina; Lübke, Andreas M; Hinsch, Andrea; Clauditz, Till; Graefen, Markus; Heinzer, Hans; Huland, Hartwig; Minner, Sarah; Sauter, Guido; Wilczak, Waldemar; Schlomm, Thorsten; Simon, Ronald.

in: CANCER MANAG RES, Jahrgang 10, 2018, S. 5909-5917.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Kluth, M, Volta, H, Hussein, M, Taskin, B, Frogh, S, Möller-Koop, C, Büscheck, F, Jacobsen, F, Tsourlakis, MC, Lübke, AM, Hinsch, A, Clauditz, T, Graefen, M, Heinzer, H, Huland, H, Minner, S, Sauter, G, Wilczak, W, Schlomm, T & Simon, R 2018, 'Deletion of 3p13 is a late event linked to progression of TMPRSS2:ERG fusion prostate cancer', CANCER MANAG RES, Jg. 10, S. 5909-5917. https://doi.org/10.2147/CMAR.S172637

APA

Kluth, M., Volta, H., Hussein, M., Taskin, B., Frogh, S., Möller-Koop, C., Büscheck, F., Jacobsen, F., Tsourlakis, M. C., Lübke, A. M., Hinsch, A., Clauditz, T., Graefen, M., Heinzer, H., Huland, H., Minner, S., Sauter, G., Wilczak, W., Schlomm, T., & Simon, R. (2018). Deletion of 3p13 is a late event linked to progression of TMPRSS2:ERG fusion prostate cancer. CANCER MANAG RES, 10, 5909-5917. https://doi.org/10.2147/CMAR.S172637

Vancouver

Kluth M, Volta H, Hussein M, Taskin B, Frogh S, Möller-Koop C et al. Deletion of 3p13 is a late event linked to progression of TMPRSS2:ERG fusion prostate cancer. CANCER MANAG RES. 2018;10:5909-5917. https://doi.org/10.2147/CMAR.S172637

Bibtex

@article{ecc5f548a48843b8b76ac59ee68086a1,
title = "Deletion of 3p13 is a late event linked to progression of TMPRSS2:ERG fusion prostate cancer",
abstract = "Introduction: Deletion of 3p13 is one of the most common alterations in prostate cancer preferentially occurring in tumors with TMPRSS2:ERG fusion. The cause for the striking association between 3p13 loss and ERG fusion is unknown.Methods: Here, we made use of a preexisting heterogeneity prostate cancer tissue microarray including ten tissue spots from ten different tumor areas of 317 cancers to examine the spatial distribution of 3p13 deletions (determined by fluorescence in situ hybridization) in prostate cancer areas with and without ERG overexpression (determined by immunohistochemistry).Results: 3p13 deletions were found in 61 of 299 (20.4%) and ERG positivity in 174 of 317 (54.9%) interpretable cancers. The likelihood of 3p13 loss was twice as high in ERG-positive cancers (39/152, 25.7%) than in ERG-negative cancers (17/124, 13.7%, P=0.010). At least three tissue spots were interpretable for 3p13 deletion status in 279 cancers: only these were used for heterogeneity assessment. Among these tumors, 58 (20.8%) had a 3p13 deletion and 221 (79.2%) were undeleted. The majority of 3p13-deleted cancers showed marked intratumoral heterogeneity. Areas with and without 3p13 loss were found in 50 (18%) of 279 cancers with three or more interpretable tissue spots, while only eight (3%) tumors had a homogeneous 3p13 loss. Comparison with ERG data revealed that ERG fusion usually precede 3p13 deletions. In total, 26 (66.7%) of 39 cancers with ERG and 3p13 alteration had only focal 3p13 deletions in an otherwise ERG-positive background. In contrast, none of the cancers showed a pattern that would be consistent with 3p13 deletion preceding ERG fusion.Conclusion: Our study identifies 3p13 deletion as a highly heterogeneous alteration in prostate cancer preferentially developing at rather late stages of progression in TMPRSS2:ERG fusion-positive tumors.",
keywords = "Journal Article",
author = "Martina Kluth and Heinke Volta and Mohammad Hussein and Billurvan Taskin and Sohall Frogh and Christina M{\"o}ller-Koop and Franziska B{\"u}scheck and Frank Jacobsen and Tsourlakis, {Maria Christina} and L{\"u}bke, {Andreas M} and Andrea Hinsch and Till Clauditz and Markus Graefen and Hans Heinzer and Hartwig Huland and Sarah Minner and Guido Sauter and Waldemar Wilczak and Thorsten Schlomm and Ronald Simon",
year = "2018",
doi = "10.2147/CMAR.S172637",
language = "English",
volume = "10",
pages = "5909--5917",
journal = "CANCER MANAG RES",
issn = "1179-1322",
publisher = "DOVE MEDICAL PRESS LTD",

}

RIS

TY - JOUR

T1 - Deletion of 3p13 is a late event linked to progression of TMPRSS2:ERG fusion prostate cancer

AU - Kluth, Martina

AU - Volta, Heinke

AU - Hussein, Mohammad

AU - Taskin, Billurvan

AU - Frogh, Sohall

AU - Möller-Koop, Christina

AU - Büscheck, Franziska

AU - Jacobsen, Frank

AU - Tsourlakis, Maria Christina

AU - Lübke, Andreas M

AU - Hinsch, Andrea

AU - Clauditz, Till

AU - Graefen, Markus

AU - Heinzer, Hans

AU - Huland, Hartwig

AU - Minner, Sarah

AU - Sauter, Guido

AU - Wilczak, Waldemar

AU - Schlomm, Thorsten

AU - Simon, Ronald

PY - 2018

Y1 - 2018

N2 - Introduction: Deletion of 3p13 is one of the most common alterations in prostate cancer preferentially occurring in tumors with TMPRSS2:ERG fusion. The cause for the striking association between 3p13 loss and ERG fusion is unknown.Methods: Here, we made use of a preexisting heterogeneity prostate cancer tissue microarray including ten tissue spots from ten different tumor areas of 317 cancers to examine the spatial distribution of 3p13 deletions (determined by fluorescence in situ hybridization) in prostate cancer areas with and without ERG overexpression (determined by immunohistochemistry).Results: 3p13 deletions were found in 61 of 299 (20.4%) and ERG positivity in 174 of 317 (54.9%) interpretable cancers. The likelihood of 3p13 loss was twice as high in ERG-positive cancers (39/152, 25.7%) than in ERG-negative cancers (17/124, 13.7%, P=0.010). At least three tissue spots were interpretable for 3p13 deletion status in 279 cancers: only these were used for heterogeneity assessment. Among these tumors, 58 (20.8%) had a 3p13 deletion and 221 (79.2%) were undeleted. The majority of 3p13-deleted cancers showed marked intratumoral heterogeneity. Areas with and without 3p13 loss were found in 50 (18%) of 279 cancers with three or more interpretable tissue spots, while only eight (3%) tumors had a homogeneous 3p13 loss. Comparison with ERG data revealed that ERG fusion usually precede 3p13 deletions. In total, 26 (66.7%) of 39 cancers with ERG and 3p13 alteration had only focal 3p13 deletions in an otherwise ERG-positive background. In contrast, none of the cancers showed a pattern that would be consistent with 3p13 deletion preceding ERG fusion.Conclusion: Our study identifies 3p13 deletion as a highly heterogeneous alteration in prostate cancer preferentially developing at rather late stages of progression in TMPRSS2:ERG fusion-positive tumors.

AB - Introduction: Deletion of 3p13 is one of the most common alterations in prostate cancer preferentially occurring in tumors with TMPRSS2:ERG fusion. The cause for the striking association between 3p13 loss and ERG fusion is unknown.Methods: Here, we made use of a preexisting heterogeneity prostate cancer tissue microarray including ten tissue spots from ten different tumor areas of 317 cancers to examine the spatial distribution of 3p13 deletions (determined by fluorescence in situ hybridization) in prostate cancer areas with and without ERG overexpression (determined by immunohistochemistry).Results: 3p13 deletions were found in 61 of 299 (20.4%) and ERG positivity in 174 of 317 (54.9%) interpretable cancers. The likelihood of 3p13 loss was twice as high in ERG-positive cancers (39/152, 25.7%) than in ERG-negative cancers (17/124, 13.7%, P=0.010). At least three tissue spots were interpretable for 3p13 deletion status in 279 cancers: only these were used for heterogeneity assessment. Among these tumors, 58 (20.8%) had a 3p13 deletion and 221 (79.2%) were undeleted. The majority of 3p13-deleted cancers showed marked intratumoral heterogeneity. Areas with and without 3p13 loss were found in 50 (18%) of 279 cancers with three or more interpretable tissue spots, while only eight (3%) tumors had a homogeneous 3p13 loss. Comparison with ERG data revealed that ERG fusion usually precede 3p13 deletions. In total, 26 (66.7%) of 39 cancers with ERG and 3p13 alteration had only focal 3p13 deletions in an otherwise ERG-positive background. In contrast, none of the cancers showed a pattern that would be consistent with 3p13 deletion preceding ERG fusion.Conclusion: Our study identifies 3p13 deletion as a highly heterogeneous alteration in prostate cancer preferentially developing at rather late stages of progression in TMPRSS2:ERG fusion-positive tumors.

KW - Journal Article

U2 - 10.2147/CMAR.S172637

DO - 10.2147/CMAR.S172637

M3 - SCORING: Journal article

C2 - 30510458

VL - 10

SP - 5909

EP - 5917

JO - CANCER MANAG RES

JF - CANCER MANAG RES

SN - 1179-1322

ER -